The European Medicines Agency is investigating Novo Nordisk's weight-loss medications after the watchdog received multiple reports of potential suicide risks, the agency announced on Monday.
According to the European Medicines Agency, two cases of suicide thoughts connected to Novo Nordisk's Ozempic and Saxenda are being examined by a safety committee.
According to the organisation, Saxenda also had another case where people had suicidal ideas.
The EMA is looking at these potential side effects in regard to medications used to treat obesity that have semaglutide or liraglutide as active components.
There is no mention of suicidal behaviour as a side effect in the EU product labelling for these medications at this time.
The European Medicines Agency (EMA) will decide whether the review should be expanded to include additional drugs from the same family, known as GLP-1 receptor agonists.
Semaglutide is the active component in Novo's obesity medications Wegovy and Ozempic, which are licenced for use in diabetic patients, while Saxenda contains liraglutide.
Patient safety, according to Novo, is a key concern, and the business takes all reports of unfavourable incidents very seriously.
"GLP-1 receptor agonists have been used to treat type 2 diabetes for more than 15 years and for treatment of obesity for 8 years, including Novo Nordisk products such as semaglutide and liraglutide that have been on the market for more than 10 years," it said.
(Source:www.nasdaq.com)
According to the European Medicines Agency, two cases of suicide thoughts connected to Novo Nordisk's Ozempic and Saxenda are being examined by a safety committee.
According to the organisation, Saxenda also had another case where people had suicidal ideas.
The EMA is looking at these potential side effects in regard to medications used to treat obesity that have semaglutide or liraglutide as active components.
There is no mention of suicidal behaviour as a side effect in the EU product labelling for these medications at this time.
The European Medicines Agency (EMA) will decide whether the review should be expanded to include additional drugs from the same family, known as GLP-1 receptor agonists.
Semaglutide is the active component in Novo's obesity medications Wegovy and Ozempic, which are licenced for use in diabetic patients, while Saxenda contains liraglutide.
Patient safety, according to Novo, is a key concern, and the business takes all reports of unfavourable incidents very seriously.
"GLP-1 receptor agonists have been used to treat type 2 diabetes for more than 15 years and for treatment of obesity for 8 years, including Novo Nordisk products such as semaglutide and liraglutide that have been on the market for more than 10 years," it said.
(Source:www.nasdaq.com)
Homepage
Send to a friend
Printable version
Share
